What it is
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) modified for an extended half-life. It is used in physician-supervised protocols to support the body’s own pulsatile release of growth hormone from the pituitary. It is frequently paired with ipamorelin, a growth hormone releasing peptide that acts on a complementary receptor.
CJC-1295 is not an FDA-approved pharmaceutical. It is compounded for off-label use under physician supervision. Patients with diagnosed growth hormone deficiency should be managed by an endocrinologist with FDA-approved recombinant growth hormone, not a compounded peptide. CJC-1295 is used in a different clinical context — supporting age-related decline in the GH axis under medical supervision.
How Dr. Brown approaches it
Peptide therapy at Esvie begins with a clinical consultation, not a phone order. Dr. Brown reviews your history, the indication you are seeking treatment for, baseline labs where appropriate, and any contraindications before CJC-1295 is prescribed.
If CJC-1295 is appropriate, a written protocol — dose, frequency, timing relative to sleep, duration, and monitoring plan — is provided. The peptide is sourced from a licensed compounding pharmacy. Protocols typically run three to six months with structured breaks. Patients with malignancy risk factors or other contraindications are not candidates.
What to expect
Consultation: An in-person visit with Dr. Brown. Medical history, baseline labs as indicated, discussion of realistic outcomes, and screening for contraindications.
Treatment cycle: Subcutaneous injection, typically administered before bed to align with the body’s natural overnight growth hormone pulse. Most patients self-administer at home after instruction.
Monitoring: Check-ins at intervals through the cycle. Labs may be repeated to assess response and safety. Adjustments to dose, frequency, or duration happen based on clinical picture.
No downtime, no aftercare: Injection sites may be mildly tender briefly; nothing more.
Candidacy
Good candidates are adults with documented decline in the growth hormone axis or related concerns — sleep quality, recovery, body composition — that warrant physician-supervised peptide therapy. Realistic expectations and willingness to commit to a full cycle matter.
Not a candidate if you are pregnant or nursing. Not a candidate with active untreated malignancy. Not a candidate with diagnosed growth hormone deficiency that requires formal endocrine care. Not a candidate seeking performance enhancement outside a clinical indication.
If CJC-1295 is not appropriate, Dr. Brown will say so and discuss alternatives — sermorelin, lifestyle work, or referral to endocrinology when warranted.